The most invasive part of brain surgery is often the first step: getting in. For decades, that has meant drilling through the skull. A San Diego startup, Vonova, is betting that a better route already exists, woven through the body's own vascular highways. The company's Cerebro platform is a catheter-based system designed to navigate blood vessels to reach the brain's surface, aiming to deliver therapies or perform procedures without a single burr hole [vonova.io, retrieved 2024].
For patients facing neurological conditions, the potential reduction in trauma, infection risk, and recovery time is significant. Vonova's initial focus, however, is pragmatic. It is aiming its first tool, the Cerebro Clear system, at a specific and sizable problem: chronic subdural hematoma (cSDH), a market its lead investor values at $1.6 billion [SmartGateVC, September 2024]. This is a long way from the speculative frontiers of brain-computer interfaces; it is a deliberate, clinical wedge into a real surgical workflow.
A neurosurgeon's invention, an engineer's build
The company's foundation is a classic medtech pairing. Dr. José Morales, the co-founder and chief medical officer, is the device's inventor and a practicing neurointerventional surgeon at the University of Arkansas for Medical Sciences [ORCID, retrieved 2024]. He brings over 15 years of research experience to the problem of brain access [vonova.io, retrieved 2024]. The clinical need is not an abstraction for him; it is the daily reality of his operating room.
His partner, CEO Wesley Jones, is the engineering co-founder tasked with turning the concept into a regulated device. Jones spent a decade developing 11 devices for giants like Medtronic and Acutus Medical, experience that spans from concept to commercialization in the highly structured world of cardiac arrhythmia technology [LinkedIn, retrieved 2024]. This combination,surgeon-inventor and seasoned device operator,is the kind of team early-stage medical investors look for, providing both clinical credibility and a realistic path through the FDA's labyrinthine Class II or III device pathway.
The clinical wedge: draining a $1.6 billion pool of blood
Vonova's strategic pivot to cSDH is a textbook example of de-risking a platform technology. A chronic subdural hematoma is a pool of blood that slowly collects between the brain and its outermost covering, often after a minor head injury in older adults. The standard of care involves drilling one or two burr holes in the skull to drain the fluid, a procedure that, while common, carries inherent risks of bleeding, infection, and recurrence.
The Cerebro Clear system proposes a different approach. Guided by real-time imaging, the catheter would travel through the vascular system to the site, potentially allowing for minimally invasive drainage [vonova.io, retrieved 2024]. Success here would prove the core access technology in a defined indication with a clear surgical customer base,neurosurgeons and neurointerventionalists. It is a focused beachhead from which the company could later expand the platform to other applications, such as delivering drugs or placing recording grids for epilepsy surgery, as earlier company materials suggested [Neurofounders, retrieved 2026].
The company reported completing preclinical testing for Cerebro Clear in mid-2025, a critical milestone on the path to human trials [Med-Tech World, June 2025]. The table below outlines the key components of Vonova's early-stage trajectory.
| Element | Detail | Source |
|---|---|---|
| Founded | 2019 | [vonova.io, retrieved 2024] |
| Headquarters | San Diego, United States | [vonova.io, retrieved 2024] |
| Lead Seed Investor | SmartGateVC | [SmartGateVC, September 2024] |
| Disclosed Seed Funding | $1,000,000 | [SmartGateVC, September 2024] |
| Initial Clinical Target | Chronic Subdural Hematoma (cSDH) | [SmartGateVC, September 2024] |
| Estimated cSDH Market Size | $1.6 billion | [SmartGateVC, September 2024] |
| Latest Development Milestone | Completed preclinical testing (June 2025) | [Med-Tech World, June 2025] |
The long road from preclinical to patient
The ambition is clear, but the path for a novel neurovascular device is among the most challenging in medtech. Vonova's current seed funding of $1 million is a start, but it is a fraction of the capital required to shepherd a device through clinical trials and toward a regulatory submission. The company will need to secure a substantial Series A in the near term to finance those studies. Furthermore, while the team has strong device development experience, navigating a first-in-human trial and building a commercial organization for a surgical product are separate challenges that lie ahead.
The competitive landscape is another open question. While no direct competitors are named in public materials, the field of minimally invasive neurosurgery is active. Larger, well-capitalized medical device companies have deep R&D pipelines and established sales forces. Vonova's answer likely rests on the specificity of its vascular access approach and the surgeon-led design of its tools,advantages that can be compelling in a specialty-driven field. The company has also attracted advisory support from industry veterans like Scott Robinson, formerly of Alphatec Spine, which may help bridge the gap to commercial strategy [Scott Robinson - Alphatec Spine | LinkedIn, retrieved 2026].
For now, the company's reported metrics,an estimated revenue of $598,885 and an estimated valuation of $2 million,should be viewed as very early snapshots from a pre-revenue device developer [Prospeo, retrieved 2026]. The real value is being built in the lab and, soon, the clinic.
What to watch in the next twelve months
The immediate milestones for Vonova are regulatory and financial. The next major step is initiating its first-in-human clinical study for the Cerebro Clear system. Securing an Investigational Device Exemption (IDE) from the FDA to begin that trial will be a pivotal moment, validating the agency's initial comfort with the safety premise. Concurrently, the company will almost certainly be raising a Series A round to fund the trial's execution. The caliber of the lead investor in that round will be a strong signal of institutional belief in the technology's clinical and commercial potential.
The patient population at the heart of this endeavor is older adults, often on blood thinners, who develop a chronic subdural hematoma after a seemingly minor bump on the head. For them, the standard of care today is a trip to the operating room for a craniotomy or burr hole surgery,procedures that carry not only the risks of any brain surgery but also the burden of a longer hospital stay and a more difficult recovery. Vonova's bet is that a gentler path through the veins can lead to a better outcome. It is a humane engineering challenge, and one that begins with draining a pool of blood to clear the way for everything that might follow.
Sources
- [vonova.io, retrieved 2024] Vonova company website | https://www.vonova.io/
- [SmartGateVC, September 2024] SmartGateVC announces investment in Vonova | https://www.smartgate.vc/post/smartgatevc-announces-investment-in-vonova-a-pioneer-in-catheter-based-brain-interface-technology
- [Med-Tech World, June 2025] Vonova Raises Funds for Brain Access Tech | https://med-tech.world/news/vonova-brain-access-tech-funding/
- [LinkedIn, retrieved 2024] Vonova company LinkedIn page | https://www.linkedin.com/company/vonovaneuro
- [ORCID, retrieved 2024] ORCID profile for Dr. José Morales | https://orcid.org/0000-0001-8837-4506
- [Neurofounders, retrieved 2026] Vonova startup profile | https://www.neurofounders.co/startups/vonova
- [Prospeo, retrieved 2026] Vonova Revenue, Funding & Valuation estimates | https://prospeo.io/c/vonova-revenue
- [Scott Robinson - Alphatec Spine | LinkedIn, retrieved 2026] LinkedIn profile showing advisory role | https://www.linkedin.com/in/scott-robinson-132b3828/